Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392054 | 0.86 | SMN1; SMN2 (0.59) | PRKDCSMN1; SMN2MAPK1P2RX4CYP19A1 | |
| SCHEMBL5444182 | 0.73 | PRKDC (1.00) | PRKDCSMN1; SMN2P2RX4POLBCYP19A1 | |
| SCHEMBL9584516 | 0.73 | POLB (0.51) | PRKDCSMN1; SMN2P2RX4POLBCYP19A1 | |
| SCHEMBL8711799 | 0.71 | CYP19A1 (0.48) | PRKDCSMN1; SMN2POLBCYP19A1ALDH1A1 | |
| SCHEMBL27968937 | 0.71 | SIGMAR1 (0.51) | PRKDCSMN1; SMN2MAPK1POLBALDH1A1 | |
| SCHEMBL4805631 | 0.71 | PIK3CG (0.58) | PRKDCSMN1; SMN2PIK3CGALDH1A1MAPT | |
| SCHEMBL8713847 | 0.70 | PRKDC (0.48) | PRKDCPOLBALDH1A1KDM4EPIK3CA | |
| Propiolactone SCHEMBL28023955 | 0.70 | CYP19A1 (0.68) | PRKDCSMN1; SMN2MAPK1P2RX4CYP19A1 | |
| SCHEMBL9740521 | 0.70 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPK1P2RX4CYP19A1ALDH1A1 | |
| SCHEMBL6902224 | 0.69 | CCR2 (0.67) | PRKDCPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1026/4885SMN1; SMN2 1402/4885MAPK1 273/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1026/4885SMN1; SMN2 1402/4885MAPK1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.